FINANCIAL TRUST COMPANY INC ACCT. For the Period 3/1/12 to 3/31/12 Note P indicates position adjusted for Pending Trade Activity. Unrealized Gain Loss is shown as "N A" in cases where we do not have appropriate cost information for all lax lots comprising the position. Please contact your J P Morgan team for additional information. Equity Detail Price Quantity Value Adjusted Tax Cost Unrealized Gain toss Est. Annual Inc Original Cost Accrued Div. Yield US Large Cap Equity ARIAD PHARMACEUTICALS INC 15.98 16,535.000 264,229.30 251,475.52 12,753.78 04033A-10-0 ARIA BIOGEN IDEC INC 126.00 2095 000 263,970.00 250,454.95 13,515.05 09062X-10-3 BIIB DB CONT BUFF E0 MS 08/07/12 91.64 1.009.000 000 916,400.00 1,000,000.00 (83,600.00) 25% CONTIN BARRIER- 1 3%CPN 30% CAP INITIAL LEVEL-07,1511 MS 21 09 2515A1-A7-6 P DOLLAR GENERAL CORP 46.20 MOO 256677-10-6 DG P DUNIUN BRANDS GROUP INC 30.06 0.00 1.99% 265504-10-0 DNKN HSBC MARKET PLUS SPX 06117/13 102.72 5,000,000.000 5,136,000.00 5,000,000.00 136.000.00 72% KO BARRIER- 096CPN ,UNCAPPED INITIAL LEVEL-02/14/12 SPX:1350.50 4042K1-XQ-1 JP Morgan Account Page 5 of 32 Consolidated Statement Page 8 Confidential Treatment Requested by JPMorgan Chase CONFIDENTIAL JPM-SDNY-00015736 SDNY_GM_00284934 EFTA01492917